DOCSLIB.ORG

Undiagnosed Liver Diseases

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Undiagnosed Liver Diseases 14 Review Article Undiagnosed liver diseases Emily Gao1#, Julian Hercun2#, Theo Heller2, Sílvia Vilarinho1,3 1Department of Internal Medicine, Section of Digestive Diseases, Yale School of Medicine, New Haven, CT, USA; 2Translational Hepatology Section, National Institute of Diabetes & Digestive & Kidney Diseases, National Institute of Health, Bethesda, MD, USA; 3Department of Pathology, Yale School of Medicine, New Haven, CT, USA Contributions: (I) Conception and design: All authors; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: None; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. #These authors contributed equally to this work. Correspondence to: Theo Heller, MD. Liver Diseases Branch, National Institute of Diabetes & Digestive & Kidney Diseases, National Institute of Health, Building 10, Room 10N248A 10 Center Drive, Bethesda, MD, 20814, USA. Email: [email protected]; Silvia Vilarinho, MD, PhD. Departments of Internal Medicine (Digestive Diseases) and of Pathology, Yale School of Medicine, 333 Cedar Street, LMP1080, New Haven, CT 06510, USA. Email: [email protected]. Abstract: The landscape of chronic liver disease has drastically changed over the past 20 years, largely due to advances in antiviral therapy and the rise of metabolic syndrome and associated non-alcoholic fatty liver disease (NAFLD). Despite advances in the diagnosis and treatment of a variety of liver diseases, the burden of chronic liver disease is increasing worldwide. The first step to addressing any disease is accurate diagnosis. Here, we discuss liver diseases that remain undiagnosed, either because they are difficult to diagnose or due to hepatic manifestations of an unrecognized systemic disease. Additionally, their underlying etiology may remain unknown or they represent previously uncharacterized and therefore novel liver diseases. Our goal is to provide a framework for approaching undiagnosed liver diseases which elude standard hepatic diagnostic work-up and whose patterns of disease are often overlooked. Keywords: Idiopathic liver disease; cryptogenic cirrhosis (CC); unmet medical need Received: 10 December 2019; Accepted: 19 March 2020; Published: 05 April 2021. doi: 10.21037/tgh.2020.04.04 View this article at: http://dx.doi.org/10.21037/tgh.2020.04.04 Introduction illustrate our incomplete understanding of the overall prevalence of liver dysfunction; and at this point in time, Chronic liver disease is the 11th leading cause of death in the spectrum of molecular pathogenesis and natural history the US and its incidence has been rising in the developing of liver disease remain unexplained in a significant number world with no signs of abatement (1-3). Many patients with of patients. abnormal liver function tests are asymptomatic, making The absence of a definitive diagnosis indicates a lack the prevalence of liver dysfunction among the general of understanding as to why an individual develops liver population difficult to ascertain. In a retrospective study of disease, which severely limits appropriate treatment and 354 adult patients with abnormal liver function tests who prognostication for these patients. Firstly, when studying underwent liver biopsy, 6% of patients had normal liver idiopathic liver disease, many studies tend to agglomerate histology and 9% of patients had hepatitis of unknown all cases of idiopathic liver disease into a single group. Such etiology (4). Moreover, a prospective study of 272 adults studies compare the demographics, clinical features and with 6 months of persistently abnormal liver function tests outcomes of individuals with undiagnosed liver disease to identified no etiology for such abnormalities in nearly individuals with a well-defined diagnosis of liver disease 20% of this group of patients (5). Altogether, these studies (6-9). Secondly, many of these comparative studies tend © Translational Gastroenterology and Hepatology. All rights reserved. Transl Gastroenterol Hepatol 2021;6:28 | http://dx.doi.org/10.21037/tgh.2020.04.04 Page 2 of 14 Translational Gastroenterology and Hepatology, 2021 Table 1 A proposed approach to undiagnosed liver disease When evaluating a patient with undiagnosed liver disease, consider whether it might be… 1. A hidden liver disease Is it an underdiagnosis or a misdiagnosis of a well-characterized hepatic disease? 2. A disguised liver disease Could it be a hepatic manifestation of a well-characterized disease better known for its extra-hepatic presentation (i.e., cystic fibrosis)? 3. A known liver disease of unknown cause Is it a well-characterized liver phenotype with unknown etiology (i.e., biliary atresia, PSC)? 4. An unknown liver disease Could it be a novel liver disease with uncharacterized clinical features, natural history and unknown cause? to be limited to small case series (7-9). It is important to also discuss undiagnosed stage of liver disease and provide recognize that this approach is deeply flawed since it merges recommendations regarding how to approach liver diseases data from several diseases with distinct pathogeneses, of unknown etiology. creating an “average” of “diseases” that do not exist and therefore inapplicable to patient care. The hidden known liver diseases Cryptogenic cirrhosis (CC) defined as cirrhosis of unknown etiology after unraveling extensive testing (10) Liver disease can remain undiagnosed and undetected until exemplifies this concept. The decreasing prevalence of clinical manifestations become apparent. Common liver CC over the past 40 years reflects the progress made in diseases, such as viral hepatitis and NAFLD, can remain diagnosing idiopathic liver disease (11). Specifically, the silent for decades. These known liver diseases often evade discovery of hepatitis B virus (HBV) in 1965, hepatitis C routine detection and their diagnosis depends on improved virus (HCV) in 1989 and the concomitant development of screening and awareness. Additionally, liver related serological testing, led to the recognition that viral hepatitis mortality due to viral hepatitis might be underreported infections were responsible for a large number of cases of (13,14). This well-recognized cause of liver disease can cirrhosis. Moreover, improvement in the definition and have severe consequences in at risk populations, including identification of autoimmune hepatitis in the last three immunocompromised and chronic liver disease patients. decades and increasing recognition of non-alcoholic fatty Viral hepatitis has the potential to remain silent due liver disease (NAFLD) as a cause of hepatic dysfunction to underdiagnosis resulting from failure to screen in further explained additional cases of cirrhosis. Today, we appropriate populations or from false-negative screening all recognize that each etiology (viral, autoimmune, among tests. Although major advances in the field of chronic others) has its own distinct treatment and overall prognosis HCV infection over the last three decades have led to safe (6,12). curative therapies for millions of infected people (15) and Here, we examine several broad categories of increased public awareness, testing for HCV is undertaken undiagnosed liver disease, which span from atypical far too infrequently. In the primary care setting, there is presentations of known diseases to uncharacterized liver concerning data showing that only 16% of patients with disorders. Specifically, we describe four broad categories consistently elevated transaminases underwent serological of undiagnosed liver disease: (I) the hidden liver disease, testing for HCV (16). which consists of underdiagnosis or misdiagnosis of well- Hepatitis D virus (HDV) is also routinely undertested. characterized hepatic disease; (II) the disguised liver In a cohort of HBV positive American veterans only 7.8% disease, which includes hepatic manifestations of broader were co-tested for HDV (17), while in a European cohort well-characterized diseases better known for extrahepatic only 30% of HBV positive patients were co-tested (18), presentation (i.e., cystic fibrosis); (III) the known liver despite recommendations for more widespread HDV disease of unknown cause, such as well-characterized liver testing. Nonetheless, even if appropriate screening in at risk phenotypes with unknown etiology [i.e., biliary atresia (BA)], patients is performed, there is a possibility of false negatives. and (IV) the unknown liver diseases, encompassing novel For example, occult HBV infection, defined as detectable liver diseases with uncharacterized phenotypic features, HBV DNA in HBV surface antigen (HBsAg) negative natural history and unknown cause (Table 1). Lastly, we will individuals, remains a public health danger in HBV endemic © Translational Gastroenterology and Hepatology. All rights reserved. Transl Gastroenterol Hepatol 2021;6:28 | http://dx.doi.org/10.21037/tgh.2020.04.04 Translational Gastroenterology and Hepatology, 2021 Page 3 of 14 regions such as Africa and Asia, where recent population potentially underrepresented and improving HEV RNA studies suggest a prevalence of 8–26% (19-23). screening tools, many have advocated for a more widespread Failure to screen for or to detect viral hepatitis occurs testing of blood products, as already established in several not only in asymptomatic patients but can lead to missed European countries including Ireland, France, Germany, diagnoses or misdiagnosis in
Load more

Recommended publications
  • Novel Hepatitis D-Like Agents in Vertebrates and Invertebrates
    bioRxiv preprint doi: https://doi.org/10.1101/539924; this version posted February 4, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Novel hepatitis D-like agents in vertebrates and invertebrates 2 3 4 Wei-Shan Chang1, John H.-O. Pettersson1, Callum Le Lay1, Mang Shi1, Nathan Lo1, Michelle 5 Wille2, John-Sebastian Eden1,3, Edward C. Holmes1 6 7 8 1Marie Bashir Institute for Infectious Diseases and Biosecurity, Charles Perkins Centre, 9 School of Life and Environmental Sciences and Sydney Medical School, The University of 10 Sydney, Sydney, NSW 2006, Australia; [email protected] (WSC); 11 [email protected] (MS); [email protected] (ECH); 12 [email protected] (JP); [email protected] (NL) 13 2WHO Collaborating Centre for Reference and Research on Influenza, at The Peter Doherty 14 Institute for Infection and Immunity, Melbourne, VIC 3000, Australia; 15 [email protected] (MW) 16 3Westmead Institute for Medical Research, Centre for Virus Research, Westmead NSW, 17 2145; Australia; [email protected] (JSE); 18 19 20 * Correspondence: [email protected]; Tel.: +61 2 9351 5591 21 bioRxiv preprint doi: https://doi.org/10.1101/539924; this version posted February 4, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • HEPATITIS D the Most Virulent Hepatitis Virus of All
    HEPATITIS D The Most Virulent Hepatitis Virus Of All The hepatitis D virus is perhaps the most unique of all hepatitis viruses, and also the most virulent. As a virus, it is flawed. The hepatitis D virus (HDV) cannot replicate and infect someone unless the person is already infected with the hepatitis B virus (HBV). The hepatitis D virus requires the outer coating of the hepatitis B virus—called the surface antigen—in order to reproduce itself in a human host. The virus currently infects 15 million worldwide, nearly all adults, and it is most common among injecting drug user populations and in countries bordering the Mediterranean Sea. Most children with HDV infection live in Italy and Greece, with a few in northern Africa. There are no reports or estimates of There are two types of HDV infection, the number of children infected with coinfection and super-infection: HDV worldwide. • Coinfection occurs when a patient is Despite widespread hepatitis B in simultaneously infected with HDV and Asian populations, HDV infection is HBV. The majority of these patients virtually unknown there and appears completely recover but there is a higher rate of fulminant hepatic failure and primarily in injecting drug user death than with HBV infection alone. populations. • Super-infection occurs when someone HDV is transmitted through blood and with an existing chronic HBV infection body fluids, similar to the hepatitis B becomes infected with HDV. These patients usually experience a sudden virus. Hepatitis D symptoms are worsening of liver disease. Patients with similar to other viral hepatitis diseases hepatitis B who become chronically and include jaundice, fever, malaise, infected with HDV experience a very dark urine and nausea.
    [Show full text]
  • Risk Groups: Viruses (C) 1988, American Biological Safety Association
    Rev.: 1.0 Risk Groups: Viruses (c) 1988, American Biological Safety Association BL RG RG RG RG RG LCDC-96 Belgium-97 ID Name Viral group Comments BMBL-93 CDC NIH rDNA-97 EU-96 Australia-95 HP AP (Canada) Annex VIII Flaviviridae/ Flavivirus (Grp 2 Absettarov, TBE 4 4 4 implied 3 3 4 + B Arbovirus) Acute haemorrhagic taxonomy 2, Enterovirus 3 conjunctivitis virus Picornaviridae 2 + different 70 (AHC) Adenovirus 4 Adenoviridae 2 2 (incl animal) 2 2 + (human,all types) 5 Aino X-Arboviruses 6 Akabane X-Arboviruses 7 Alastrim Poxviridae Restricted 4 4, Foot-and- 8 Aphthovirus Picornaviridae 2 mouth disease + viruses 9 Araguari X-Arboviruses (feces of children 10 Astroviridae Astroviridae 2 2 + + and lambs) Avian leukosis virus 11 Viral vector/Animal retrovirus 1 3 (wild strain) + (ALV) 3, (Rous 12 Avian sarcoma virus Viral vector/Animal retrovirus 1 sarcoma virus, + RSV wild strain) 13 Baculovirus Viral vector/Animal virus 1 + Togaviridae/ Alphavirus (Grp 14 Barmah Forest 2 A Arbovirus) 15 Batama X-Arboviruses 16 Batken X-Arboviruses Togaviridae/ Alphavirus (Grp 17 Bebaru virus 2 2 2 2 + A Arbovirus) 18 Bhanja X-Arboviruses 19 Bimbo X-Arboviruses Blood-borne hepatitis 20 viruses not yet Unclassified viruses 2 implied 2 implied 3 (**)D 3 + identified 21 Bluetongue X-Arboviruses 22 Bobaya X-Arboviruses 23 Bobia X-Arboviruses Bovine 24 immunodeficiency Viral vector/Animal retrovirus 3 (wild strain) + virus (BIV) 3, Bovine Bovine leukemia 25 Viral vector/Animal retrovirus 1 lymphosarcoma + virus (BLV) virus wild strain Bovine papilloma Papovavirus/
    [Show full text]
  • Nadia Khamees Sanaa Halabiah
    pbl Nadia khamees Sanaa Halabiah PBL lecs1+2: Introduction to clinical manifestations of some of the common GI disorders: - Upper GI Bleeding - liver cirrhosis and portal hypertension - Viral Hepatitis A-E Upper GI Bleeding Bleeding that originates above the ligament of Treitz. Signs and Symptoms ► Hematemesis; vomiting fresh blood. ► Melena; a loose shiny black tarry offensive smell stool. ► Dizziness; due to hypotension and volume loss. ► Abdominal pain and symptoms of peptic ulcer disease. ► Pallor due to anemia. ► Hypotension. ► Orthostasis; a drop in the blood pressure while the patient becomes in a standing position due to hypotension. it may precede that frank hypotension. So, to any patient with upper GI bleeding, we have to measure his blood pressure while he is supine and while he is standing because he may have normal blood pressure while he is supine and his blood pressure will drop upon standing up. ► Jaundice and other stigmata of chronic liver diseases ► Hematochezia; massive fresh bleeding which is not having the time to convert to the black color of melena. ► Coffee ground vomiting. ► they usually report a history of non-steroidal anti-inflammatory drug use. Causes of upper GI bleeding ► Peptic ulcer disease “gastric and duodenal ulcers” (the most common) ► Esophageal varies ► Mallory- Weiss tear ► Erosions other uncommon causes: ► malignancy ► arterial-venous malformations ► Hemobilia due to collagen carcinoma. ► Aorto-enteric fistulas; occurs in patients with an aortic aneurysm that did surgery for that aneurysm and a fistula then forms between the colon and the aorta which causes massive bleeding. ► Neoplasms ► AVM/Ectasia ► Dieulafoy’s ► Stoma ulcers ► Esophageal ulcers ► Duodenitis We will talk about some of these causes: Peptic ulcer disease A defect in the GI mucosa that extends through their muscularis mucosa, caused by an imbalance between the aggressive and defensive factors.
    [Show full text]
  • Hepatitis D Chapter
    HEPATITIS D Also known as: Viral hepatitis D, Hepatitis delta virus, Delta agent hepatitis, Delta associated hepatitis Responsibilities: Hospital: Report by IDSS, facsimile, mail, or phone Lab: Report by IDSS, facsimile, mail, or phone Physician: Report by facsimile, mail, or phone Local Public Health Agency (LPHA): Follow-up required Iowa Department of Public Health Disease Reporting Hotline: (800) 362-2736 Secure Fax: (515) 281-5698 1) THE DISEASE AND ITS EPIDEMIOLOGY A. Agent Hepatitis delta virus (HDV) is a small virus-like particle made up of a hepatitis B surface antigen and the delta antigen and a single strand of DNA. It cannot infect a cell itself; it can only replicate if there is a co-infection with hepatitis B virus (HBV). Infection with HDV can occur at the same time as HBV or can occur at a later date in a person with chronic hepatitis B. B. Clinical Description Symptoms: Signs and symptoms resemble hepatitis B and may be severe. These symptoms are fatigue, nausea, vomiting, fever, stomach pain, tea-colored urine, and jaundice. The infection may be self-limiting or it may progress to chronic infection. Children may have a very severe course of disease. Infection with HDV in a person with chronic hepatitis B may be misdiagnosed as a worsening of hepatitis B. One quarter to one half of fulminant cases of hepatitis B (those that are rapidly fatal) are associated with concurrent infection with HDV. Onset: is usually sudden. Complications: of hepatitis D are the same as that of hepatitis B. Infection can lead to rapid death from liver cell necrosis or the infection can become chronic, leaving the person a carrier of disease and may lead to cirrhosis of the liver or liver cancer.
    [Show full text]
  • Table of Contents
    TABLE OF CONTENTS Clinical Course and Clinical Manifestation . .6 Book 7 Diagnosis . .7 Managing of Hepatitis B . .7 Preface . .i Prevention . .7 Hepatitis B Vaccine . .7 Editorial Board . ii Postexposure . .8 Chronic Hepatitis B . .9 Book 7 Panel . .iii Interferon . .9 Lamivudine . .9 Disclosure of Potential Conflicts of Interest . .ix Adefovir Dipivoxil . .10 Recommendations for Treating Continuing Education and Program Evaluation HBeAg-positive CHB . .11 Instructions . .x Recommendations for Treating HBeAg-negative CHB . .11 Roles of ACCP and BPS . .xiii Investigational Drugs for CHB . .12 Entecavir . .12 Clevudine . .12 Gastroenterology I Emtricitabine . .13 Telbivudine . .13 VIRAL HEPATITIS Pegylated Interferons . .13 Learning Objectives . .1 Hepatitis C . .13 Introduction . .1 Virology and Pathogenesis . .14 History . .1 Epidemiology and Risk Factors . .14 Definitions of Acute and Chronic Hepatitis . .1 Natural History . .14 Hepatitis A . .1 Clinical Course and Clinical Manifestation . .14 Virology and Pathogenesis . .1 Diagnosis and Serological Testing . .15 Epidemiology and Risk Factors . .2 Managing Hepatitis C . .15 Clinical Course and Clinical Manifestations . .2 Prevention . .15 Diagnosis and Serological Testing . .3 Treating Hepatitis C . .16 Managing of Hepatitis A . .3 HIV/HCV Coinfection . .18 Preexposure Prophylaxis . .4 Treating Recurrent HCV after Liver Postexposure Prophylaxis . .4 Transplantation . .18 Hepatitis A Vaccine . .4 Treating Nonresponders . .19 Treatment . .5 Treatment Duration for Hepatitis C . .20 Hepatitis B . .5 Side Effects Associated with HCV Therapy Virology and Serology . .5 and Management . .20 Epidemiology . .6 Flu-like Symptoms . .20 Risk Factors . .6 Psychological Symptoms . .20 Natural History . .6 Hematological Adverse Effects . .20 Pharmacotherapy Self-Assessment Program, 5th Edition xv Table of Contents Anemia . .20 Measurements of Intestinal Transit and Motility .
    [Show full text]
  • Rotaviral Gastroenteritis in the NT: a Description of the Epidemiology 1995-2001 and Future Directions for Research
    The Northern Territory Disease Control Bulletin Vol 8, No.3, September 2001 1 Vol. 8, No. 3 , September 2001 ISSN 1440-883X Rotaviral Gastroenteritis in the NT: a description of the epidemiology 1995-2001 and future directions for research Paul Armstrong, CDC Darwin and MAE program, NCEPH, ANU, Canberra Introduction after which it quickly established itself as second in importance to the G1 serotype 2. The emergence of In 2001, the Northern Territory (NT) experienced these serotypes has important implications for fu- the largest outbreak of gastroenteritis due to human ture vaccine development. rotavirus since surveillance records for the disease were begun in 1994. Epidemics of rotavirus are not Contents uncommon in the NT and sporadic infection con- tinues in the inter-epidemic periods. When gastro- Rotaviral gastroenteritis in the NT: a description of enteritis epidemics due to this organism do occur, the epidemiology, 1995-2001 and future directions for research ................................................................ 1 there is a severe strain on the health services. In a national study analysing hospitalisation rates for Knowledge and practices of sexually transmitted diseases by general practitioners in the Top End acute gastroenteritis in young children, the NT was of Australia ................................................................ 6 shown to have the highest admission rates for acute 1 Factors affecting hepatitis A vaccination uptake gastroenteritis and for rotavirus . The length of among childcare workers in the NT ........................ 10 hospital stay was 3 to 5 times longer than any of Hepatitis A outbreak in Darwin Aug—Dec 2000 ... 13 the states. The reasons for the higher hospitalisa- Firework related injuries during Territory Day tion rates and length of hospital stay have not been celebrations 2001 ...................................................
    [Show full text]
  • Enteric Hepatitis Viruses1
    Enteric hepatitis viruses1 Description The term “hepatitis viruses” refers to a diverse group of viruses all of which have the human liver as the primary target of replication and give rise to hepatitis or inflammation of the liver. Their replication may result in mass destruction of liver cells. Consequences include failure of the liver to fulfil basic functions such as removal of bilirubin from the circulatory blood system. Bilirubin is a red pigment released from red blood cells as they break down and are replaced by new cells. Excessive accumulation of the pigment in the bloodstream is manifest as yellow coloration of sites such as the eyes and the palms of the hands. This condition is known as jaundice and is also marked by dark urine and stools result- ing from the excretion of bilirubin. Another typical consequence of massive liver cell damage is release into the bloodstream of liver enzymes, including alanine transaminase (ALT) and aspartate transaminase (AST). Serum levels of these enzymes are used to diagnose hepatitis (Zuckerman & Thomas, 1993). Hepatitis may also be caused by other systemic pathogens such as cyto- megalovirus, yellow fever virus, and Leptospira bacteria, although the liver is not the primary or only target of these organisms. Liver cell damage and jaundice may also be caused by toxic compounds, including alcohol. Since the clinical symptoms caused by hepatitis viruses are very similar, and some of the viruses only emerged on a large scale in recent years, distinction of different aetiological agents has been progressively accomplished only since the 1960s. The first two hepatitis viruses that were distinguished were simply 1 This review was prepared by W.O.K.
    [Show full text]
  • Had Severe Relapses
    Correspondence 747 Gut: first published as 10.1136/gut.27.6.747 on 1 June 1986. Downloaded from assessment. The combination of a distressed restless HBsAg positive, but usually discharged from the patient and a stomach containing a large volume of hospital. One can argue these might be considered blood may decrease the chances of accurately cases of HDV superinfection. The detection of identifying the cause of bleeding. In these circum- serum bAg in four of these during the first acute stances it is usually easier to assess the antrum and episode, as well as the uneventful course of the duodenal cap. If these are clear, attention should disease in all the subjects, are against this hypo- then be directed at the upper half of the stomach. A thesis.3 4 Lack of follow up in parenteral drug useful manoeuvre in these circumstances is to dilate abusers with acute HBV/HDV coinfection may the stomach with air when small lesions may become produce an underestimate of the prevalence of apparent. The diagnostic return more than balances relapses. Because of the possible asymptomatic the slight extra risk involved. Experience in Black- course of the relapse, this error might be increased. pool suggests that in haemorrhage associated with We think that parenteral drug abusers with acute multiple gastric erosions which is recurrent or HBsAg positive hepatitis must be followed up with persistent, dilatation of the stomach may show that frequent clinical, biochemical, and serological tests bleeding occurs from one minute lesion, usually high until clearance of HBsAg. in the stomach and involving a submucosal artery.
    [Show full text]
  • Hepatitis Chart
    THE TEXAS GUIDE TO SCHOOL HEALTH PROGRAMS 473 Hepatitis Chart Hepatitis A1 Hepatitis B2 Hepatitis C3 Hepatitis D4 Hepatitis E 5 WHAT IS IT? A virus causing A virus causing Most common bloodborne A virus causing A virus causing inflammation of the liver, it inflammation of the liver, it inflammation of the viral infection in the US; inflammation of the is rare in the US and is not associated with a does not lead to chronic liver, it can cause liver 60% to 70% develop liver, it only infects chronic state. disease. cell damage leading to chronic hepatitis; cirrhosis those with hepatitis cirrhosis and cancer. develops in 10% to 20% B. with chronic hepatitis C over 20-30 yrs; hepatocellular carcinoma (liver cancer) in 1% to 5%; INCUBATION 15 to 50 days. Average 30 4 to 25 weeks. Average 2 to 25 weeks, Avg 7- 4 to 26 weeks Avg 40 days; Range 15-60 days PERIOD days 8 to 12 weeks 9wks. HOW IS IT Fecal/oral route, through Contact with infected Contact with infected Contact with Transmitted primarily by the fecal-oral route. SPREAD? close person-to-person blood, seminal fluid and blood, contaminated IV infected blood, Fecally contaminated drinking water is the contact or ingestion of vaginal secretions. Sex needles, razors, contaminated most commonly documented vehicle of contaminated food and contact, contaminated tattoo/body piercing, and needles. Sexual transmission. Person-to -person transmission water. needles, tattoo/body other sharp instruments. contact with is uncommon., nosocomial transmission piercing and other sharp Infected mother to hepatitis D infected presumably by person- to-person contact, has instruments.
    [Show full text]
  • CDHO Advisory Viral Hepatitis, 2020-05-19
    CDHO Advisory | Viral H epatitis COLLEGE OF DENTAL HYGIENISTS OF ONTARIO ADVISORY ADVISORY TITLE Use of the dental hygiene interventions of scaling of teeth and root planing including curetting surrounding tissue, orthodontic and restorative practices, and other invasive interventions for persons1 with viral hepatitis. ADVISORY STATUS Cite as College of Dental Hygienists of Ontario, CDHO Advisory Viral Hepatitis, 2020-05-19 INTERVENTIONS AND PRACTICES CONSIDERED Scaling of teeth and root planing including curetting surrounding tissue, orthodontic and restorative practices, and other invasive interventions (“the Procedures”). SCOPE DISEASE/CONDITION(S)/PROCEDURE(S) Viral hepatitis INTENDED USERS Advanced practice nurses Nurses Dental assistants Patients/clients Dental hygienists Pharmacists Dentists Physicians Denturists Public health departments Dieticians Regulatory bodies Health professional students ADVISORY OBJECTIVE(S) To guide dental hygienists at the point of care relative to the use of the Procedures for persons who have viral hepatitis, chiefly as follows. 1. Understanding the medical condition. 2. Sourcing medications information. 3. Taking the medical and medications history. 4. Identifying and contacting the most appropriate healthcare provider(s) for medical advice. 1 Persons includes young persons and children Page | 1 CDHO Advisory | Viral H epatitis 5. Understanding and taking appropriate precautions prior to and during the Procedures proposed. 6. Deciding when and when not to proceed with the Procedures proposed. 7. Dealing
    [Show full text]
  • Hepatitis D Virus Fact Sheet
    Hepatitis D Infection Fact Sheet (adapted from materials developed by the Centers for Disease Control and Prevention) Report to Minnesota • Report the following to the Minnesota Department of Health: Department of Health o Hepatitis D infection • Report to the Minnesota Department of Health by any of the following methods: o Phone: 651-201-5414 or 1-877-676-5414 (toll free) o Fax: 651-201-5501 o Mail: Minnesota Department of Health Disease Report Card P.O. Box 64975 St. Paul, MN 55164-0975 Etiology • Hepatitis D virus (HDV) is a defective, single-stranded RNA virus that requires the helper function of the hepatitis B virus (HBV) to replicate. Signs and Symptoms • HDV infection causes hepatitis only in persons with acute or chronic HBV infection; the HDV cannot produce infection in the absence of HBsAg. • Symptoms are indistinguishable from HBV infection, whether HBV-HDV co-infection (simultaneously acquired) or superinfection (HDV acquired by a person with chronic HBV infection) • Severe acute disease and higher risk of fulminant hepatitis with HBV-HDV co-infection • The average incubation period for: o Co-infection is 90 days (range 45-160 days) o Superinfection is approximately 2-8 weeks. Long-Term Effects • Co-infection o severe acute disease o low risk of chronic infection • Superinfection o usually development of chronic HDV infection • High risk of severe chronic liver disease Transmission • Percutaneous exposure; injecting drug use • Permucosal exposure • Sexual transmission is less common • Perinatal transmission is rare • Persons at risk for HBV infection might also be at risk for infection with hepatitis C virus (HCV) or HIV Communicability • Persons with HBV-HDV superinfection are the primary reservoirs of infection.
    [Show full text]